Table 4.
Genetic and Clinical Determinants of Metabolic Syndrome: Logistic Regression Model Coefficients from Prospective Cohort of Patients Prescribed Clozapine (n = 59).
| Variable | Effect Size | |
|---|---|---|
| Effect (B) | P Value | |
| Smoking | –0.3745 | 0.750 |
| Clozapine level | 0.00106 | 0.0148* |
| CYP2C19*2 | –1.5919 | 0.033* |
| CYP1A2*1F A/A | –2.507 | 0.0213* |
| LEPR c.668 A/G | –2.594 | 0.0252* |
| LEPR c.668 G/G | –3.028 | 0.0204* |
| Smoker: CYP1A2*1FA/A | 4.0318 | 0.0188* |
Adjusted for sex and age. Covariates considered included smoking, family history of cardiovascular disease and diabetes, diagnosis of diabetes or cardiovascular disease, concurrent medications reported to increase body mass index, clozapine dose and clozapine blood level, and genetic markers in CYP1A2, CYP2C19, ABCB1, HTR2C, LEPR, and LEP genes.
*P < 0.05.